Oramed Pharmaceuticals Inc (ORMP) - Total Assets
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) holds total assets worth $220.49 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Oramed Pharmaceuticals Inc (ORMP) net assets for net asset value and shareholders' equity analysis.
Oramed Pharmaceuticals Inc - Total Assets Trend (2005–2024)
This chart illustrates how Oramed Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Oramed Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Oramed Pharmaceuticals Inc's total assets of $220.49 Million consist of 92.2% current assets and 7.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 35.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2005–2024)
This chart illustrates how Oramed Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Oramed Pharmaceuticals Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Oramed Pharmaceuticals Inc's current assets represent 92.2% of total assets in 2024, a decrease from 100.0% in 2005.
- Cash Position: Cash and equivalents constituted 35.1% of total assets in 2024, up from -3209.1% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Oramed Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Oramed Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Oramed Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 22.24 | 27.08 | 6.27 |
| Quick Ratio | 22.24 | 27.08 | 6.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $130.00 Million | $137.50 Million | $30.28 Million |
Oramed Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Oramed Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.63 |
| Latest Market Cap to Assets Ratio | 0.83 |
| Asset Growth Rate (YoY) | -29.6% |
| Total Assets | $155.28 Million |
| Market Capitalization | $129.51 Million USD |
Valuation Analysis
Near Book Valuation: The market values Oramed Pharmaceuticals Inc's assets close to their book value (0.83x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Oramed Pharmaceuticals Inc's assets decreased by 29.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Oramed Pharmaceuticals Inc (2005–2024)
The table below shows the annual total assets of Oramed Pharmaceuticals Inc from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $155.28 Million | -29.60% |
| 2023-12-31 | $220.55 Million | +36.44% |
| 2022-12-31 | $161.64 Million | +26.28% |
| 2021-12-31 | $128.00 Million | +186.78% |
| 2020-12-31 | $44.63 Million | +28.76% |
| 2019-12-31 | $34.66 Million | -26.87% |
| 2018-12-31 | $47.40 Million | +22.43% |
| 2017-12-31 | $38.71 Million | -9.61% |
| 2016-12-31 | $42.83 Million | +62.52% |
| 2015-12-31 | $26.35 Million | +20.88% |
| 2014-12-31 | $21.80 Million | +151.75% |
| 2013-12-31 | $8.66 Million | +63.56% |
| 2012-12-31 | $5.29 Million | +22.40% |
| 2011-12-31 | $4.33 Million | +198.16% |
| 2010-12-31 | $1.45 Million | -55.52% |
| 2009-12-31 | $3.26 Million | -40.77% |
| 2008-12-31 | $5.51 Million | +184.31% |
| 2007-12-31 | $1.94 Million | +999.38% |
| 2006-12-31 | $176.19K | +13883.33% |
| 2005-12-31 | $1.26K | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more